FDA Grants Breakthrough Therapy Designation to Relay’s Zovegalisib for Advanced Breast Cancer
Event summary
- FDA granted Breakthrough Therapy Designation to zovegalisib (RLY-2608) in combination with fulvestrant for PIK3CA-mutant, HR+/HER2- advanced breast cancer.
- Designation supported by Phase 1/2 ReDiscover trial data with 600mg BID fasted and 400mg BID fed doses.
- Initial Phase 1/2 data of zovegalisib + fulvestrant at the 400mg BID fed (Phase 3 dose) to be presented at ESMO Targeted Anticancer Therapies Congress on March 16, 2026.
- Zovegalisib is the first allosteric, pan-mutant, and isoform-selective PI3Kα inhibitor designed to overcome limitations of traditional PI3Kα inhibitors.
The big picture
Relay Therapeutics’ Breakthrough Therapy Designation for zovegalisib underscores the growing emphasis on precision medicine in oncology. The designation accelerates the development of targeted therapies for PIK3CA-mutant breast cancer, a subset with limited treatment options. This strategic milestone positions Relay to compete in the crowded PI3Kα inhibitor space, leveraging its proprietary Dynamo® platform to differentiate its candidate.
What we're watching
- Regulatory Acceleration
- How the Breakthrough Therapy Designation will expedite zovegalisib’s development and review process, potentially shortening the path to market.
- Clinical Data Impact
- Whether the upcoming presentation of Phase 1/2 data at ESMO will reinforce zovegalisib’s clinical profile and investor confidence.
- Market Potential
- The pace at which Relay Therapeutics can capitalize on the unmet need in PIK3CA-mutant, HR+/HER2- advanced breast cancer.
Related topics